This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

Avir BD execs on innovative meds for Canadians

Posted by on 14 July 2017
Share this article

Located in Quebec, Canada, Avir Pharma, a specialty pharma company, is part of the Laboratoire Riva group. Its primary focus is to acquire, license or co-develop innovative medicines with an end aim of getting these novel medicines launched and available to Canadian patients. Avir's business development associate, Vanessa Fortin, and VP of business development, Kaled Kadri, chat to Scrip about the company's commercial strategy and key therapy areas of focus. Kadir also discusses reimbursement differences in the Canadian pharmaceutical market and why a business model focused on commercialization, not R&D, works in this region.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip

  • Kaled Kadri – VP Business Development, Avir Pharma
  • Vanessa Fortin – Associate Business Development, Avir Pharma
Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down